Gland Pharma Invests $21M in US Subsidiary, Novelstar Pharma
Gland Pharma Limited's Board of Directors has approved an investment of USD 21 million in its proposed wholly-owned subsidiary, Gland Pharma USA Inc. (Gland USA). Gland USA will utilize these funds to acquire a 60% equity stake in Novelstar Pharma Inc. (Novelstar). This strategic investment aims to expand Gland Pharma's business operations in the United States. Upon completion, Novelstar will become a subsidiary of Gland USA and a step-down subsidiary of Gland Pharma. The filing also announced the resignation of Director Mr. Wenjie Zhang and the appointment of Mr. Xingli Wang as an Additional Director, leading to a realignment of Board Committees.
Key Highlights
- Gland Pharma invests $21 million in its US subsidiary, Gland USA.
- Gland USA will acquire a 60% stake in Novelstar Pharma Inc.
- The investment aims to expand Gland Pharma's US market presence.
- Novelstar will become a step-down subsidiary of Gland Pharma.
- Director resignation and new appointment approved by the Board.
Price Impact
More from GLAND
Gland Pharma: Director Resigns, New Director Appointed; Invests $21M in US Subsidiary
Gland Pharma Invests USD 21M in US Subsidiary for Novelstar Acquisition
Fosun Pharma Sells Gland Pharma Shares, Stake Drops to 45.41%